Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
pegylated consensus interferon mutant
- Development stage
- Unknown
- Lead developer
- 三元基因
- Modality
- Cytokines & Interferons → Recombinant Proteins and Enzymes
- Administration
- Parenteral
01
Overview
A PEGylated recombinant protein biologic developed by Beijing Tri-Prime Gene Pharmaceutical for the treatment of chronic hepatitis B. It is a long-acting interferon mutant designed to provide prolonged interferon-alpha activity and enhanced antiviral effects compared to standard formulations. As an IFNAR agonist, it induces an innate antiviral immune response and acts as an immunostimulant. The drug is currently in Phase 1 clinical development in China, where studies have evaluated its safety, tolerability, and pharmacokinetic/pharmacodynamic profiles in healthy subjects and patients with chronic hepatitis B.
- Other names
- 新型PEG集成干扰素突变体注射液Novel PEGylated integrated interferon mutant injectionNovel PEG-Consensus Interferon Mutant Injectionpegylated integrated interferon mutant
02
Targets
IFNAR (Immune system modulation via type I interferon receptor)
Beyond the preview
Go deeper on pegylated consensus interferon mutant.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on pegylated consensus interferon mutant.